Clinical and pharmacological group: & nbsp

Immunoglobulins

Included in the formulation
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    J.06.B.B.02   Human tetanus antiglobulin

    Pharmacodynamics:

    Neutralizes tetanus toxin.

    Pharmacokinetics:

    After intramuscular injection, the maximum concentration in the blood plasma is reached after 24-48 hours.

    The half-life is 3-4 weeks.

    Indications:

    It is used for emergency prevention of tetanus in children and adults.

    XXI.Z20-Z29.Z23.5   The need for immunization against tetanus alone

    XXI.Z20-Z29.Z29.1   Prophylactic immunotherapy

    Contraindications:

    Individual intolerance.

    Carefully:

    Presence of allergic reactions in the anamnesis.

    Pregnancy and lactation:

    Recommendations for FDA - category is not defined. It is used for life indications.

    Dosing and Administration:

    Intramuscularly for the purpose of prevention: 250 IU for children and adults.

    In the treatment of tetanus, the dose is 3-6 thousand IU: it is divided and injected into different places.

    The highest daily dose: 6 thousand IU.

    The highest single dose: 6 thousand IU.

    Side effects:

    Local (edema, infiltration at the injection site) and allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Compatible with all drugs, including antibiotics.

    Reduces the effectiveness of active immunization against rubella, chicken pox, measles, mumps. It is recommended to use antiviral vaccines 3 months after the application of the anti-staphylococcal immunoglobulin.

    Special instructions:

    In case of emergency prophylaxis of tetanus immunoglobulin and anatoxin, drugs must be administered to different areas of the body using different syringes.

    Instructions
    Up